This month, the Wisconsin Medical Society adopted a no-gifts, no-exceptions policy for its 12,000 plus members, stating that a “complete ban eases the burdens of compliance, biased decision making, and patient distrust.”  In addition, the policy prevents

The American Gastroenterological Association has issued guidelines on the management of Gastroesophageal Reflux Disease (GERD), which can be loosely described as persistent and troublesome heartburn or asymptomatic reflux that causes esophageal injury. Th

Thanks to Patent Baristas for tipping us off to the latest online pharmaceutical Flash-plugin board game craze, Biologicsland! Biologicsland is brought to you by the wacky folks over at Teva Pharmaceuticals. Teva (NASDAQ:TEVA) is the largest generic dru

This week, House Energy and Commerce Committee Chair John Dingell (D-Mich) and Oversight and Investigations Subcommittee Chair Bart Stupak (D-Mich.) sent a letter to the FDA asking about just how and why the agency chose non-profit EthicAd to partner on t

It's being widely reported this morning (See, for example, the WSJ article here and the AP article here) that Pfizer (NYSE:PFE) has agreed to settle the bulk of the lawsuits against it related to the increased risk of heart attacks and strokes from the pa

Prescription Access Litigation’s parent organization, Community Catalyst, launched a new program this summer in conjunction with the Alosa Foundation called Generics are Powerful Medicine. Generics are Powerful Medicine (GPM) is a national project to edu

Prescription Access Litigation's blog is now a regular feature on Wellsphere's Health Blogger commuinty. You'll find us in the Health Industry and Policy Community. Prescription Access Litigation Healthcare Industry & Policy Community PAL's blog

A conversation with Michael Hochman, MD A study this month in the Journal of the American Medical Association found the mainstream news media isn’t passing muster when it comes to sussing out industry bias in pharmaceutical research. Investigators looked

Back in April the PAL fortune teller made some bold predictions about GlaxoSmithKline’s (NYSE:GSK) new migraine drug Treximet. (’GlaxoSmithKline sets out to dupe migraine sufferers with Treximet smoke and mirrors“). Treximet is nothing more than a combi